Bristol Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Bristol Advisors’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-250,000	Closed	-$72K	–	94
2018 Q2	$72K	Buy	250,000 +60,000	+32%	+$292K	0.14%	52
2018 Q1	$76K	Buy	190,000 +30,000	+19%	+$140K	0.25%	26
2017 Q4	$6K	Buy	+160,000	New	+$882K	﹤0.01%	80
2017 Q3	–	Sell	-180,000	Closed	-$149K	–	86
2017 Q2	$149K	Buy	+180,000	New	+$1.12M	0.1%	50

Bristol Advisors's KERX Position: Q4 2018 in Review

Bristol Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 51,100 shares — an estimated $174K sold.

Bristol Advisors first reported a position in KERX in Q3 2017 and held it in 5 quarters. The position peaked at $889K in Q4 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

Bristol Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
Bristol Advisors sold 51,100 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $174K.
Bristol Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q3 2017 and held it in 5 quarters.
Bristol Advisors's Keryx Biopharmaceuticals Inc position peaked at $889K in Q4 2017.
1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Bristol Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.